An OMERACT Initiative Toward Consensus to Identify and Characterize Candidate Contextual Factors: Report from the Contextual Factors Working Group.

Date publication

mai 2017

Journal

The Journal of rheumatology

Auteurs

Membres identifiés du Cancéropôle Est :
Pr GUILLEMIN Francis

Tous les auteurs :
Finger ME, Boonen A, Woodworth TG, Escorpizo R, Christensen R, Nielsen SM, Leong AL, Scholte Voshaar M, Flurey CA, Milman N, Verstappen SM, Alten R, Guillemin F, Kloppenburg M, Beaton DE, Tugwell PS, March LM, Furst DE, Pohl C

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/28461648

Résumé

The importance of contextual factors (CF) for appropriate patient-specific care is widely acknowledged. However, evidence in clinical trials on how CF influence outcomes remains sparse. The 2014 Outcome Measures in Rheumatology (OMERACT) Handbook introduced the role of CF in outcome assessment and defined them as "potential confounders and/or effect modifiers of outcomes in randomized controlled trials." Subsequently, the CF Methods Group (CFMG) was formed to develop guidance on how to address CF in clinical trials.

Mots clés

CONTEXTUAL, EFFECT MODIFIER, OMERACT, PATIENT-REPORTED OUTCOMES, RANDOMIZED CONTROLLED TRIALS, RHEUMATOLOGY

Référence

J. Rheumatol.. 2017 May;: